These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24803511)

  • 1. Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.
    Wiegand RE; Rose CE; Karon JM
    Stat Methods Med Res; 2016 Dec; 25(6):2733-2749. PubMed ID: 24803511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
    Flandre P; Marcelin AG; Calvez V;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):448-454. PubMed ID: 28653971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 5. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
    Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
    J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.
    Santos JR; Blanco JL; Masiá M; Gutiérrez F; Pérez-Elías MJ; Iribarren JA; Force L; Antela A; Knobel H; Salavert M; López Bernaldo De Quirós JC; Pino M; Paredes R; Clotet B; ;
    J Antimicrob Chemother; 2015 Nov; 70(11):3087-95. PubMed ID: 26490727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
    Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
    J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.
    Heredia A; Hassounah S; Medina-Moreno S; Zapata JC; Le NM; Han Y; Foulke JS; Davis C; Bryant J; Redfield RR; Wainberg MA
    J Antimicrob Chemother; 2017 Sep; 72(9):2570-2573. PubMed ID: 28637235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.
    Watanabe D; Ibe S; Uehira T; Minami R; Sasakawa A; Yajima K; Yonemoto H; Bando H; Ogawa Y; Taniguchi T; Kasai D; Nishida Y; Yamamoto M; Kaneda T; Shirasaka T
    BMC Infect Dis; 2011 May; 11():146. PubMed ID: 21605468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Yeni P; Strohmaier KM; Rodgers AJ; Barnard RJ; Nguyen BY; Teppler H;
    Antivir Ther; 2015; 20(3):307-15. PubMed ID: 25350973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV encephalitis in a patient on antiretroviral therapy: a case report.
    Hlebowicz M; Parczewski M; Jakubowski P
    Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).
    Andrade A; Guedj J; Rosenkranz SL; Lu D; Mellors J; Kuritzkes DR; Perelson AS; Ribeiro RM;
    AIDS; 2015 Nov; 29(18):2419-26. PubMed ID: 26558541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to salivary human immunodeficiency virus type-1 levels measured by a Poisson distribution-based PCR method.
    Ikeno R; Yamada E; Yamazaki S; Ueda T; Nagata M; Takagi R; Kato S
    J Int Med Res; 2018 Mar; 46(3):996-1007. PubMed ID: 29119839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
    Troya J; Ryan P; Montejano R; Cabello A; Cuevas G; Matarranz M; Cañamares I; Solís J; Walther LÁ
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):423-426. PubMed ID: 30443683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.